1. CysLT1R expression on ILC2s and effects of CysLT1R antagonist on ILC2 activity in patients with allergic rhinitis.
- Author
-
Qin, Zi‐Li, Peng, Ya‐Qi, Fang, Shu‐Bin, Jiang, Ai‐Yun, Li, Cheng‐Lin, Fan, Xing‐Liang, Chen, Dong, Chen, Wen‐Na, Bellanti, Joseph.A., Zheng, Song Guo, and Fu, Qing‐Ling
- Subjects
ALLERGIC rhinitis ,ANDROGEN receptors ,THYMIC stromal lymphopoietin ,INNATE lymphoid cells - Abstract
To the Editor, Group 2 innate lymphoid cells (ILC2s) produce the canonical type 2 cytokines interleukin (IL)-5 and IL-13 in response to epithelial cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP).[1] ILC2s have been to be involved in the pathogenesis of asthma, allergic rhinitis (AR) and atopic dermatitis (AD).[2] We have reported the higher ILC2 levels in patients with asthma and patients with AR.[[3]] Recently, the cysteinyl leukotriene (CysLT) D4 (LTD4) and LTE4 were reported to induce Th2 cytokine production from ILC2s.[[5]] LTE4 is the stable and dominant CysLT in the pathogenesis of allergic conditions. We found higher prevalence of ILC2s (Lin SP - sp CRTH2 SP + sp CD127 SP + sp cells, Figure A) and the higher expression of CysLT1R in ILC2s (Figure B-C B ) b from patients with AR compared to healthy controls. It suggests that the activation of ILC2s to LTC4, LTD4 but not LTE4 in AR is related to the increased expression of CysLT1R in AR, at least in our study. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF